We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II Results with Recombinant Interferons: Renal Cell Carcinoma and Malignant Melanoma.
- Authors
Kuzmits, R.; Kokoschka, E.M.; Micksche, M.; Ludwig, H.; Flener, R.
- Abstract
There is as yet no effective treatment for renal cell carcinoma and metastasizing malignant melanoma. This fact, coupled with in vitro investigations showing growth inhibitory or cytotoxic effects of interferon (IFN) on renal cell carcinoma and melanoma cell lines, led to phase II clinical trials with recombinant (r) IFN-α2C and rIFN-γ. So far 8 patients with renal cell carcinoma have been treated with IFN-α2c and 3 patients with rIFN-γ. There has been one complete response to IFN-α2C, two mixed responses and one partial response. One patient on rIFN-γ has stable disease and the other 2 have progressed. Eleven patients with metastasizing malignant melanoma were treated with IFN-α2C. One patient achieved a complete remission and 3 others had stable disease which later progressed in 2 of them. Side-effects were reversible. Copyright © 1985 S. Karger AG, Basel
- Publication
Oncology, 1985, Vol 42, Issue S1, p26
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000226081